

	SOT	HCT	A-CA
Symptoms			
Fever	56.3% [37.2%; 69.6%]	0.0% [0.0%; 58.5%]	88.1% [82.3%; 92.0%]
Fatigue	71.1% [54.5%; 81.6%]	0.0% [0.0%; 0.0%]	91.9% [86.3%; 95.1%]
Myalgia	76.3% [65.2%; 83.8%]	0.0% [0.0%; 0.0%]	55.1% [0.0%; 82.0%]
Cough	28.2% [0.0%; 53.3%]	0.0% [0.0%; 88.4%]	90.2% [85.7%; 93.3%]
Dyspnea	77.0% [68.3%; 83.3%]	77.7% [27.9%; 93.1%]	85.4% [77.4%; 90.5%]
Vomiting	71.6% [56.8%; 81.3%]	0.0% [0.0%; 0.0%]	0.0% [0.0%; 77.9%]
Neurologic	43.4% [6.2%; 65.8%]	0.0% [0.0%; 0.0%]	32.4% [0.0%; 71.3%]
Comorbidities			
Hypertension	80.5% [66.0%; 88.8%]	83.8% [78.4%; 87.8%]	54.3% [0.0%; 86.9%]
Diabetes	94.8% [92.6%; 96.3%]	67.9% [54.9%; 77.2%]	0.0% [0.0%; 70.6%]
Pulmonary Disease	93.2% [89.4%; 95.6%]	65.3% [47.9%; 76.9%]	32.3% [0.0%; 93.0%]
Cardiovascular Disease	86.0% [76.8%; 91.6%]	69.6% [56.1%; 78.9%]	48.7% [0.0%; 85.1%]
COVID-19 Severity			
Mild/Moderate	76.3% [66.6%; 83.2%]	0.0% [0.0%; 37.9%]	97.2% [96.1%; 98.0%]
Severe	76.3% [66.6%; 83.2%]	0.0% [0.0%; 37.9%]	97.2% [96.1%; 98.0%]
Hospital Outcome			
Intensive Care	70.7% [57.6%; 79.7%]	0.0% [0.0%; 69.0%]	97.9% [96.8%; 98.6%]
Mortality	36.0% [0.2%; 59.0%]	0.0% [0.0%; 37.4%]	92.4% [86.3%; 95.8%]
Therapy Change			
Antimetabolite	66.7% [51.2%; 77.3%]	N/A	N/A
Calcineurin Inhibitor	92.5% [90.4%; 94.1%]	N/A	N/A
mTOR Inhibitor	71.5% [27.9%; 88.7%]	N/A	N/A
Antineoplastic Therapy	N/A	N/A	91.0% [80.0%; 95.9%]